Plain-English translation of NCT07674290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is tracking how well works in real-world medical practice for people with Bardet-Biedl syndrome and other rare genetic obesity disorders. is an FDA-approved medication that helps control appetite by affecting how the brain regulates hunger and energy use. The research team wants to understand how this medication affects weight, hunger levels, quality of life, and any side effects that occur during routine treatment.
While earlier clinical trials showed that this medication can help reduce severe obesity, doctors need more information about how it actually works in everyday medical practice outside of controlled research settings. This study will help doctors understand whether the medication is as effective and safe when used in regular clinics.
You likely qualify if…
You likely don't qualify if…
You would continue taking your appetite-control medication as prescribed by your doctor during regular outpatient visits. During these routine visits, the research team will collect information about your weight, hunger levels, energy, blood work results, and how the medication is affecting your daily life. The study will follow you over time to track how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Germany